𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model

✍ Scribed by Kiryo Wakabayashi; Atsushi Nagai; Abdullah Md. Sheikh; Yuri Shiota; Dashdemberel Narantuya; Tatsuzo Watanabe; Junichi Masuda; Shotai Kobayashi; Seung U. Kim; Shuhei Yamaguchi


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
581 KB
Volume
88
Category
Article
ISSN
0360-4012

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Previous studies have suggested that intravenous transplantation of mesenchymal stem cells (MSCs) in rat ischemia models reduces ischemia‐induced brain damage. Here, we analyzed the expression of neurotrophic factors in transplanted human MSCs and host brain tissue in rat middle cerebral artery occlusion (MCAO) ischemia model. At 1 day after transient MCAO, 3 × 10^6^ immortalized human MSC line (B10) cells or PBS was intravenously transplanted. Behavioral tests, infarction volume, and B10 cell migration were investigated at 1, 3, 7, and 14 days after MCAO. The expression of endogenous (rat origin) and exogenous (human origin) neurotorphic factors and cytokines was evaluated by quantitative real‐time RT‐PCR and Western blot analysis. Compared with PBS controls, rats receiving MSC transplantation showed improved functional recovery and reduced brain infarction volume at 7 and 14 days after MCAO. In MSC‐transplanted brain, among many neurotrofic factors, only human insulin‐like growth factor 1 (IGF‐1) was detected in the core and ischemic border zone at 3 days after MCAO, whereas host cells expressed markedly higher neurotrophic factors (rat origin) than control rats, especially vascular endothelial growth factor (VEGF) at 3 days and epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) at 7 days after MCAO. Intravenously transplanted human MSCs induced functional improvement, reduced infarct volume, and neuroprotection in ischemic rats, possibly by providing IGF‐1 and inducing VEGF, EGF, and bFGF neurotrophic factors in host brain. © 2009 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Intravenous administration of glial cell
✍ Yoshifumi Horita; Osamu Honmou; Kuniaki Harada; Kiyohiro Houkin; Hirofumi Hamada 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

## Abstract Intravenous administration of human mesenchymal stem cells (hMSCs) prepared from adult bone marrow has been reported to ameliorate functional deficits after cerebral artery occlusion in rats. Several hypotheses to account for these therapeutic effects have been suggested, and current th

Glial cell line-derived neurotrophic fac
✍ Aleksandra Glavaski-Joksimovic; Tamas Virag; Thomas A. Mangatu; Michael McGrogan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive degeneration of nigrostriatal dopaminergic (DA) neurons. The therapeutic potential of glial cell line‐derived neurotrophic factor (GDNF), the most potent neurotrophic factor for DA neurons, has been dem